<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Unexplained infertility</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Unexplained infertility</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Unexplained infertility</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark D Hornstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William E Gibbons, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 22, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>It is relatively simple to identify the cause of infertility in women with ovulatory disorders or tubal disease, and in men with semen abnormalities. These categories account for the source of infertility in approximately 75 to 85 percent of couples [<a href="#rid1">1</a>]. Infertility in the remaining couples is due to endometriosis (8 percent) or miscellaneous factors (eg, cervical factor, immunological factor, uterine synechiae) (2 percent) or is unexplained (15 percent) [<a href="#rid2">2-4</a>].</p><p>Management of couples with unexplained infertility will be reviewed here. Related content on the overview of infertility and evaluation of patients is presented separately: </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7396.html" rel="external">"Overview of infertility"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5445.html" rel="external">"Female infertility: Evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7453.html" rel="external">"Approach to the male with infertility"</a>.)</p><p><br/>In this topic, when discussing study results, we will use the terms "woman/en", "man/en", or "patient(s)" as they are used in the studies presented. However, we encourage the reader to consider the specific counseling and treatment needs of transgender and gender-expansive individuals.</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION AND DIAGNOSIS</span><span class="headingEndMark"> — </span>Unexplained infertility refers to the absence of a definable cause for a couple's failure to achieve pregnancy after 12 months of attempting conception despite a thorough evaluation, or after six months in women 35 and older [<a href="#rid5">5,6</a>]. Authorities vary in their concept of what constitutes a thorough evaluation, and these opinions have evolved over time. Currently, a thorough evaluation typically includes documentation of:</p><p class="bulletIndent1"><span class="glyph">●</span>Ovulation</p><p class="bulletIndent1"><span class="glyph">●</span>Tubal patency</p><p class="bulletIndent1"><span class="glyph">●</span>Normal uterine cavity</p><p class="bulletIndent1"><span class="glyph">●</span>Normal semen analysis</p><p class="bulletIndent1"><span class="glyph">●</span>Adequate ovarian oocyte reserve</p><p></p><p>A detailed description of these tests, and the role of laparoscopy in the diagnostic evaluation, can be found separately. (See  <a class="medical medical_review" href="/d/html/5445.html" rel="external">"Female infertility: Evaluation"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">POSSIBLE ETIOLOGIES</span><span class="headingEndMark"> — </span>Several possibilities have been proposed to explain why some couples fail to conceive in the absence of an identifiable cause. Subtle changes in follicle development, ovulation, and the luteal phase have been reported in some of these women [<a href="#rid7">7,8</a>]. In other couples, the male partner's semen analysis shows sperm concentration and motility at the lower end of the normal range [<a href="#rid9">9</a>]. Implantation failure, subtle cervical factors, or problems with sperm and egg transport or interaction are other possibilities [<a href="#rid10">10</a>]. Many cases of unexplained infertility are probably caused by the presence of multiple factors (eg, female partner over 35 years of age with diminished ovarian reserve and male partner with low normal semen parameters), each of which on their own do not significantly reduce fertility, but can reduce the pregnancy rate when combined.</p><p>Couples with unexplained infertility who are treated with in vitro fertilization (IVF) demonstrate reduced oocyte fertilization and embryo cleavage rates compared with couples in whom tubal factor is the cause of the infertility, although the rates of live birth per transfer are equivalent for both groups. This was illustrated in a study that showed that the oocyte fertilization and the embryo cleavage rate for unexplained and tubal factor infertility were 52 and 60 percent, respectively [<a href="#rid11">11</a>]. Couples with unexplained infertility also had a higher rate of complete fertilization failure when treated with IVF than couples with tubal factor infertility (6 versus 3 percent). These results suggest that couples with unexplained infertility probably have subtle functional abnormalities in oocyte and/or sperm function. In this sense, IVF is also a diagnostic procedure.</p><p>Defective endometrial receptivity is thought to prevent normal attachment, invasion, and implantation of the blastocyst, and may account for some cases of unexplained infertility and recurrent pregnancy loss [<a href="#rid12">12</a>]. No biomarkers have been validated for clinical diagnosis of these patients. </p><p>Undiagnosed/untreated celiac disease may be more prevalent in women with unexplained infertility. (See  <a class="medical medical_review" href="/d/html/4774.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults"</a>.)</p><p>Comprehensive genetic studies are needed to better understand the etiologies of unexplained infertility. A comprehensive, 10-year evaluation is underway by the National Institutes of Health entitled "The All Of Us Research Program," which is inviting one million people to help build one of the most diverse health databases in history; the database will combine genetic histories, lifestyle, medical conditions, and whole genome application [<a href="#rid13">13</a>]. From this information, multiple breakthroughs are expected, such as recurrent pregnancy wastage and unexplained infertility. We are signing our patients up and hope others will as well.</p><p class="headingAnchor" id="H4"><span class="h1">OUR APPROACH</span><span class="headingEndMark"> — </span>The management of couples with unexplained infertility should balance the efficacy, cost, safety, and risks of various treatment alternatives. A common approach is to start with treatments that consume few resources and are patient-directed (eg, lifestyle changes or timed intercourse), and then move sequentially to treatments requiring proportionately greater resources (<a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate [CC] plus intrauterine insemination [IUI]), and finally to high-resource interventions (gonadotropin injections plus IUI, in vitro fertilization [IVF])  (<a class="graphic graphic_table graphicRef61307" href="/d/graphic/61307.html" rel="external">table 1</a>) [<a href="#rid11">11</a>]. The approach to treatment should be individualized for each couple. In general, if a specific fertility treatment does not result in pregnancy after three cycles, alternative treatments should be considered [<a href="#rid14">14</a>]. (See <a class="local">'Lifestyle changes'</a> below and  <a class="medical medical_review" href="/d/html/5411.html" rel="external">"Natural fertility and impact of lifestyle factors"</a> and <a class="local">'Low-resource interventions'</a> below and <a class="local">'High-resource interventions'</a> below.)</p><p>Once any lifestyle issues have been addressed, we begin treatment with CC/IUI, or <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a>/IUI [<a href="#rid15">15-17</a>]. As women with unexplained infertility are ovulatory, the purpose of ovulation induction is to cause mild ovarian hyperstimulation and resultant double ovulation in normally mono-ovulatory women. CC is combined with IUI based on the hypothesis that placing a large number of sperm high in the reproductive tract enhances the likelihood of conception. (See <a class="local">'Clomiphene plus IUI'</a> below.)</p><p>For women who do not conceive with <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> or <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a>/IUI in three to four cycles of treatment, we proceed with IVF [<a href="#rid17">17</a>]. IVF is the intervention that results in the highest per-cycle pregnancy rate in the shortest time interval, with up to 40 percent of cycles resulting in a live birth [<a href="#rid18">18</a>]. However, IVF is also the most expensive treatment option. </p><p>In women for whom IVF is <strong>not</strong> an option because of insurance, financial, religious, or personal reasons, we offer either ovulation induction with injectable gonadotropins or laparoscopy. (See <a class="local">'In vitro fertilization'</a> below and <a class="local">'Gonadotropin injections with or without IUI'</a> below and  <a class="medical medical_review" href="/d/html/3279.html" rel="external">"Female infertility: Reproductive surgery"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>The section editor and one author (MH) perform laparoscopy on women with pelvic symptoms suggestive of disease, such as endometriosis, and proceed with injectable gonadotropins for women without pelvic symptoms. For symptomatic women, treatment following laparoscopy is determined by the intraoperative findings (eg, endometriosis, adhesions). </p><p></p><p class="bulletIndent1">For asymptomatic women, ovulation induction with another oral agent or gonadotropin ovulation induction and IUI is offered because this approach is established in the treatment of unexplained infertility and has higher rates of conception compared with CC/IUI or aromatase inhibitors [<a href="#rid16">16</a>]. However, patients are counseled that gonadotropin/IUI also increases the rate of multiple gestations, including triplets and greater, compared with either CC or the aromatase inhibitor <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a>. (See <a class="local">'Gonadotropin injections with or without IUI'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One author (WG) performs laparoscopy, rather than offering gonadotropin/IUI, as the next treatment step for women unable to pursue IVF. In the author's experience, a number of these women will have findings of endometriosis and/or adhesive disease at the time of laparoscopy, regardless of symptomatology, and surgical treatment of endometriosis has been associated with improved fertility [<a href="#rid19">19</a>]. After laparoscopy, another course of CC/IUI is initiated. In addition, gonadotropin/IUI is associated with a high rate of multiple gestation and increases the cost out of proportion to the modest improvement in outcome (live birth rate 32 percent for gonadotropin/IUI compared with 23 percent for CC/IUI) [<a href="#rid16">16</a>]. In the author's experience, some women who initially decline IVF and then fail other treatments will change their decision and pursue IVF rather than gonadotropin treatment because the live birth rate is higher with IVF compared with gonadotropins (45 versus 32 percent) [<a href="#rid16">16</a>] and the cost is similar. (See  <a class="medical medical_review" href="/d/html/3279.html" rel="external">"Female infertility: Reproductive surgery"</a> and <a class="local">'In vitro fertilization'</a> below.)</p><p></p><p>For women with unexplained infertility who do not conceive with CC/IUI, IVF, gonadotropin/IUI, or laparoscopy, alternate treatment options include ovulation induction with the aromatase inhibitor <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a>, donor-egg pregnancy, gestational surrogacy, adoption, and cessation of treatment. It should be noted that letrozole treatment for ovulation induction is an off-label use of this medication [<a href="#rid20">20</a>]. We believe that there is no single algorithm for women at this point in their treatment; the next steps are determined by the patient after extensive counseling by her fertility team. Additional discussions are available in related content. </p><p class="bulletIndent1"><span class="glyph">●</span>(See <a class="local">'Aromatase inhibitors plus IUI'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions", section on 'When are donor oocytes used?'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7431.html" rel="external">"Gestational carrier pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2854.html" rel="external">"Adoption"</a>.)</p><p></p><p class="headingAnchor" id="H5"><span class="h1">EXPECTANT MANAGEMENT</span><span class="headingEndMark"> — </span>One to 3 percent of couples with unexplained infertility followed prospectively without active treatment become pregnant each month [<a href="#rid21">21,22</a>]. Therefore, effective fertility treatment for unexplained infertility must demonstrate an increase in the pregnancy rate above this baseline fecundability.</p><p>The age of the female partner influences the pregnancy rate associated with expectant management [<a href="#rid23">23</a>]. Women with unexplained infertility older than 37 years of age have a pregnancy rate of less than 1 percent per cycle with expectant management. In randomized trials, six months of expectant management for couples with a good prognosis for fertility (young age, no bilateral tubal disease, no sperm problems) or an intermediate prognosis (30 to 40 percent probability of pregnancy without treatment) was associated with an ongoing pregnancy rate comparable to that achieved with intrauterine insemination plus gonadotropin injections (see below) [<a href="#rid24">24,25</a>]. Thus, expectant management may be an option for a couple with unexplained infertility in whom the female partner is less than 32 years of age and there is no immediate concern about oocyte depletion. However, the ovarian oocyte pool declines rapidly for women over 37 years of age, inevitably causing ovarian aging and depletion to become a major component of the fertility problem. Thus, expectant management is not recommended for these women.</p><p class="headingAnchor" id="H6"><span class="h1">PATIENT-CONTROLLED APPROACHES</span></p><p class="headingAnchor" id="H7"><span class="h2">Lifestyle changes</span><span class="headingEndMark"> — </span>Epidemiologic studies indicate cigarette smoking, abnormal body mass index, and excessive caffeine consumption reduce fertility in the female partner and possibly the male partner. (See  <a class="medical medical_review" href="/d/html/5411.html" rel="external">"Natural fertility and impact of lifestyle factors"</a>.)</p><p>Couples with unexplained infertility should be informed of a possible relationship between cigarette smoking and their infertility and advised to stop smoking for this reason, as well as for benefits in overall health. (See  <a class="medical medical_review" href="/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p>The female partner should be counseled to try to achieve a body mass index between 20 and 27 kg/m<sup>2</sup>, reduce caffeine intake to no more than approximately 250 mg daily (two cups of coffee), and reduce alcohol intake to no more than four standardized drinks per week [<a href="#rid26">26</a>]. These changes may be useful for enhancing both natural and assisted conception [<a href="#rid27">27,28</a>].</p><p>This is also an appropriate time to mention lifestyle changes for health promotion to the male partner for his general health benefits, and because the couple's coordinated efforts to modify their lifestyle may provide support and reinforcement for each other.</p><p class="headingAnchor" id="H8"><span class="h1">LOW-RESOURCE INTERVENTIONS</span><span class="headingEndMark"> — </span>Couples of all ages often become frustrated with their inability to conceive. Active treatment is recommended for these couples when lifestyle interventions fail to result in pregnancy. The following interventions increase the number of gametes available in a given cycle and/or facilitate the ability of the gametes to interact. These interventions have less risk and cost compared with in vitro fertilization (IVF) procedures.</p><p class="headingAnchor" id="H9"><span class="h2">Intrauterine insemination (IUI)</span><span class="headingEndMark"> — </span>For patients with unexplained infertility, IUI alone is not more likely to achieve pregnancy than expectant management [<a href="#rid17">17</a>]. However, when combined with ovarian stimulation (either <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate or aromatase inhibitors) it is an effective treatment [<a href="#rid9">9</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Procedure</strong> – IUI consists of washing an ejaculated semen specimen to remove prostaglandins and semen proteins that would promote an allergic reaction if injected into the uterus, concentrating the sperm in a small volume of culture media, and injecting the sperm suspension directly into the upper uterine cavity using a small catheter threaded through the cervix. (See  <a class="medical medical_review" href="/d/html/7413.html" rel="external">"Procedure for intrauterine insemination (IUI) using processed sperm"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supporting data</strong> – The efficacy of IUI for couples with unexplained infertility was demonstrated in a large clinical trial sponsored by the National Institutes of Health (NIH) [<a href="#rid9">9</a>]. Over 900 infertile couples with unexplained infertility were randomly assigned to one of four treatment groups:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intracervical insemination of sperm (ICI)</p><p class="bulletIndent2"><span class="glyph">•</span>IUI of sperm</p><p class="bulletIndent2"><span class="glyph">•</span>FSH injections plus ICI</p><p class="bulletIndent2"><span class="glyph">•</span>FSH injections plus IUI</p><p></p><p class="bulletIndent1">The purpose of the ICI was to act as a control treatment mimicking natural intercourse; the purpose of IUI was to place a large number of sperm high in the reproductive tract; and the purpose of FSH injections was to stimulate multiple follicular development and ovulation, thereby increasing the number of oocytes available for fertilization in a single cycle. Most of the women in this study had either unexplained infertility or early stage endometriosis.</p><p></p><p class="bulletIndent1">The investigators observed a 2 percent per cycle pregnancy rate in the group that received the control ICI treatment; this pregnancy rate is similar to that achieved with expectant management. IUI treatment was associated with a 5 percent per cycle pregnancy rate; thus, in the randomized trial, IUI alone was effective, but only marginally for the treatment of unexplained infertility.</p><p></p><p class="bulletIndent1">The pregnancy rates in the FSH-ICI and FSH-IUI groups were higher, and are described below. (See <a class="local">'Gonadotropin injections with or without IUI'</a> below.)</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Clomiphene citrate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">Clomiphene</a> alone has been demonstrated to be effective in the treatment of infertility due to oligoanovulation or anovulation. For patients with unexplained infertility, treatment with clomiphene alone is not helpful but pairing it with IUI improves outcomes [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/7400.html" rel="external">"Ovulation induction with clomiphene citrate"</a>.)</p><p>In a 2010 meta-analysis of randomized trials of unexplained subfertility treated with <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> versus placebo or no treatment, use of clomiphene alone (no IUI) did not increase the pregnancy rate per woman randomized (odds ratio [OR] 1.03, 95% CI 0.64-1.66; 2 trials, 458 participants) [<a href="#rid29">29</a>]. However, these results need to be interpreted with caution as there was significant heterogeneity between trials. In one trial, clomiphene citrate (CC) was associated with significantly more pregnancies over the course of four months, with a pregnancy rate of 19 percent versus no pregnancies with placebo [<a href="#rid30">30</a>]. A 1998 retrospective analysis of 45 published reports of treatment of unexplained infertility reported pregnancy rates of 5.6 percent with clomiphene alone versus rates of 1.3 to 4.1 percent with no treatment [<a href="#rid31">31</a>]. Based on these data, the American Society of Reproductive Medicine (ASRM) concluded that empiric use of CC with intercourse for unexplained infertility should be discouraged, but further studies are needed to provide better data on the effectiveness of this approach [<a href="#rid32">32</a>]. The ASRM Practice Committee placed significant weight on a study comparing clomiphene with expectant management and with IUI alone [<a href="#rid33">33</a>]. In this study, when multifollicular development was observed with clomiphene 50 mg, the cycle was cancelled and the subject was administered 25 mg of clomiphene for 5 days or 25 mg every other day, which is a marked variance to the standard use of clomiphene. Thus, it appears that CC use is best paired with IUI in patients with unexplained infertility. (See <a class="local">'Clomiphene plus IUI'</a> below.)</p><p>The main complication of <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> is an increase in the incidence of multiple gestation. This risk was illustrated in a study of 2369 clomiphene induced pregnancies that reported the incidence of twins, triplets, quadruplets, and quintuplets was 7, 0.5, 0.3, and 0.13 percent, respectively [<a href="#rid34">34</a>]. The risk of high-order multiple pregnancies with clomiphene treatment is low, but the high volume of clomiphene cycles makes this intervention an important contributor to the total number of high-order multiple gestations [<a href="#rid35">35</a>].</p><p>In comparative treatment trials, <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> was not as effective as gonadotropin injections [<a href="#rid36">36</a>]. (See <a class="local">'Gonadotropin injections with or without IUI'</a> below.)</p><p class="headingAnchor" id="H11"><span class="h2">Clomiphene plus IUI</span><span class="headingEndMark"> — </span>CC/IUI is generally the first-line treatment for unexplained infertility because of its good clinical pregnancy rate, relatively low rate of multiple gestations, oral route of intake, lack of need for monitoring, and low cost [<a href="#rid15">15,17,37</a>]. The combination of CC (to increase the rate of double ovulation) plus IUI (to place a large number of motile sperm high in the female reproductive tract) may simultaneously treat mild abnormalities of ovulation, oocyte function, and sperm function. In trial of 900 women with unexplained infertility randomly assigned to treatment with CC, <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a>, or gonadotropin (all combined with IUI), the clinical pregnancy rates were 28 (CC), 22 (letrozole), and 36 (gonadotropin) percent [<a href="#rid16">16</a>]. However, the rates of multiple gestation were lowest for the women treated with CC/IUI (9 percent) compared with letrozole (13 percent) or gonadotropin (32 percent). </p><p>The optimal method for timing IUI is to use a commercial kit to determine daily urinary luteinizing hormone (LH) levels starting on day 10 of the cycle. IUI is performed when urinary LH is detected. This method is as effective, but less expensive, than timing based on ultrasound monitoring of folliculogenesis with human chorionic gonadotropin (hCG) injection upon development of an appropriately sized dominant follicle, followed by IUI. This approach was supported by a systematic review showing that women who underwent hCG administration before IUI had lower clinical pregnancy rates than women who underwent IUI based on detection of urinary LH (OR 0.74, 95% CI 0.57-0.96) [<a href="#rid38">38</a>]. No cost analysis was performed. The authors concluded that the available data did not demonstrate a consistent, clinically important benefit of hCG-induced ovulation compared with spontaneous ovulation for IUI timing. Although the question of whether two IUIs per cycle is superior to a single IUI is somewhat controversial, most clinicians perform a single IUI [<a href="#rid39">39-43</a>]. </p><p>A retrospective multicenter cohort study of couples who underwent over 15,000 IUI cycles reported acceptable pregnancy rates after one to nine cycles [<a href="#rid44">44</a>]. In this series, 70 percent of the patients underwent both IUI and controlled ovarian stimulation (51 percent CC, 19 percent gonadotropins). The cumulative ongoing pregnancy rate after three, six, and nine cycles was 18, 30, and 41 percent, respectively. Thus, this study suggests that up to nine IUI cycles is an appropriate treatment course. By comparison, older literature showed that the vast majority of pregnancies occurred by the sixth treatment cycle, and relatively few occurred beyond six cycles. We typically administer three to four treatment cycles before moving on to another modality.</p><p>However, age should be taken into account; multiple treatment cycles are not beneficial in older women. One study showed that on a per patient treated basis, cumulative pregnancy rates by age were 24.2 percent under age 35, 18.5 percent ages 35 to 37, 15.1 percent ages 38 to 40, 7.4 percent ages 41 to 42, and 1.8 percent age above 42 (one pregnancy in 55 patients) [<a href="#rid45">45</a>]. In this study, there were no pregnancies beyond the fourth cycle in women age 41 and older.</p><p class="headingAnchor" id="H12"><span class="h2">Aromatase inhibitors plus IUI</span><span class="headingEndMark"> — </span>Ovarian stimulation with aromatase inhibitors (AIs) plus IUI may result in pregnancy for women with unexplained infertility who do not respond to CC plus IUI and who cannot or choose not to use IVF or gonadotropin therapy. AIs have similar clinical pregnancy, multiple gestation, and live birth rates compared with CC [<a href="#rid16">16,46,47</a>], and they are easier to use (oral dosing, no monitoring required) and less expensive compared with injectable gonadotropin therapy. Although AIs are associated with a lower clinical pregnancy rate compared with gonadotropin treatment, AIs are also associated with a lower rate of multiple gestations, including a much lower rate of triplet pregnancy. Therefore, when other treatment options do not result in pregnancy, AI treatment is a reasonable option. It should be noted that AI therapy for ovulation induction is an off-label use of this medication. (See  <a class="medical medical_review" href="/d/html/7425.html" rel="external">"Ovulation induction with letrozole"</a>.) </p><p>Support for this approach comes from a trial of 900 women, 18 to 40 years of age with unexplained infertility, who were randomly assigned to receive the AI <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a>, CC, or gonadotropin for ovulation induction in addition to timed IUI [<a href="#rid16">16</a>]. The overall live birth rates were 19 percent for the letrozole group, 23 percent for the CC group, and 32 percent for the gonadotropin group. While the birth rate was highest for women receiving gonadotropin, these women also had the highest rate of multiple births, including triplets. Multiple gestations occurred in 13 percent of the gonadotropin group, 1 percent of the CC group, and 3 percent of the letrozole group. For women receiving gonadotropin treatment, approximately 30 percent of the multiple pregnancies were triplet pregnancies. In contrast, the women receiving letrozole and CC who conceived multiple gestations had only twin pregnancies; no triplet pregnancies occurred.</p><p>Lastly, theoretical concerns that aromatase inhibitors may be teratogenic have not been supported in large trials [<a href="#rid16">16,48</a>] and a large retrospective study [<a href="#rid49">49</a>]. In the trial reviewed above, the number of infants born with congenital malformations was similar across the three treatment groups (4 percent for <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a>, 4 percent for <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a>, and 3 percent for gonadotropin) and similar to the anticipated baseline risk of major congenital malformations, which is 3 to 4 percent [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/7425.html" rel="external">"Ovulation induction with letrozole", section on 'Fetal safety'</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">HIGH-RESOURCE INTERVENTIONS</span></p><p class="headingAnchor" id="H14"><span class="h2">Gonadotropin injections with or without IUI</span><span class="headingEndMark"> — </span>In general, due to the increased risk of multiple gestations associated with gonadotropin ovulation induction/intrauterine insemination (IUI) and the increased efficacy of in vitro fertilization (IVF) compared with ovulation induction, we favor IVF rather than gonadotropin/IUI for women in whom <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate/IUI has failed [<a href="#rid17">17,50-52</a>]. In a meta-analysis of eight trials comparing gonadotropins versus oral agents with IUI for patients with unexplained infertility, gonadotropin use did not result in improved live birth rates [<a href="#rid52">52</a>]. To gain additional live births, high doses of gonadotropins with more relaxed cancellation protocols were required, which resulted in a higher risk of multiple gestation. While the lower gonadotropin dose was no better than the oral agents, with higher doses, 13 cycles were needed to treat to exceed the oral medications, but only 7 were needed to harm patients with multiple gestations. Thus, the data do not support the use of gonadotropins with IUI in patients with unexplained infertility.</p><p class="headingAnchor" id="H15"><span class="h2">In vitro fertilization</span><span class="headingEndMark"> — </span>IVF is the intervention that results in the highest per cycle pregnancy rate in the shortest time interval. It is also the most costly intervention and has a high rate of high order multiple pregnancy, unless single embryo transfer is performed [<a href="#rid53">53</a>]. In a 2012 Cochrane review of randomized trials examining the effectiveness of IVF against other treatment options in couples with unexplained infertility, live birth rates were significantly higher with IVF than with expectant management (45.8 versus 3.7 percent; 1 trial of 51 women), but comparisons with active treatments were either not available or unable to detect moderate differences in live birth rates because the studies were small and heterogeneous [<a href="#rid54">54</a>]. In a subsequent trial that randomized 154 couples with ≥6 months of unexplained infertility and female partner aged 38 to 42 years to two cycles of <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a>/IUI, two cycles of gonadotropin injections/IUI, or immediate IVF, live birth rates were: 8, 7, and 16 percent, respectively [<a href="#rid55">55</a>]. Overall, 84 percent of all pregnancies resulted from IVF. Thus, in this age group the best outcome is achieved with immediate IVF. However, an IVF cycle is several times more expensive than a clomiphene/IUI or a gonadotropin/IUI cycle.</p><p>The utility of a step-wise protocol was illustrated by a cohort study of couples with unexplained infertility in which the woman was initially treated with gonadotropin injections plus IUI for up to three cycles and then IVF was used to treat those who did not conceive [<a href="#rid56">56</a>]. The pregnancy rate with gonadotropin injections plus IUI was 15.7 percent per cycle and 29.8 percent per patient and the pregnancy rate in those who went on to IVF was 36.7 percent. (See  <a class="medical medical_review" href="/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions"</a>.)</p><p class="headingAnchor" id="H364423541"><span class="h1">ALTERNATIVE TO IN VITRO FERTILIZATION</span><span class="headingEndMark"> — </span>For women with unexplained infertility who do not pursue in vitro fertilization due to cost or other reasons, we typically offer laparoscopy as the next step after ovulation induction. Laparoscopy provides visualization of the pelvis, can identify causes for infertility and failed therapy, and allows for surgical intervention. Surgical treatment of conditions such as endometriosis or pelvic adhesions can improve fertility.</p><p class="headingAnchor" id="H16"><span class="h1">INEFFECTIVE TREATMENTS</span><span class="headingEndMark"> — </span>Clinical trials of the treatment of unexplained infertility have shown that administration of either <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a> or <a class="drug drug_general" data-topicid="9321" href="/d/drug information/9321.html" rel="external">danazol</a> was not effective [<a href="#rid57">57,58</a>].</p><p class="headingAnchor" id="H3080085400"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114191.html" rel="external">"Society guideline links: Female infertility"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15425.html" rel="external">"Patient education: Male infertility (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15424.html" rel="external">"Patient education: Female infertility (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2175.html" rel="external">"Patient education: Evaluation of infertility in couples (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/2180.html" rel="external">"Patient education: Treatment of male infertility (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/8420.html" rel="external">"Patient education: Ovulation induction with clomiphene or letrozole (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/8418.html" rel="external">"Patient education: Infertility treatment with gonadotropins (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Unexplained infertility refers to the absence of a definable cause for a couple's failure to achieve pregnancy after 12 months of attempting conception (six months in women 35 years and older) despite a thorough evaluation. (See <a class="local">'Definition and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contributing etiologies</strong> – The infertility is probably due to subtle functional abnormalities in oocyte, sperm or endometrial function. (See <a class="local">'Possible etiologies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach</strong> – The management of couples with unexplained infertility usually starts with treatments that consume few resources, are low risk, and are patient directed (eg, lifestyle changes), and then moves sequentially to treatments requiring proportionately greater resources and risks (<a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> or <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a> plus intrauterine insemination [IUI]), and finally to higher risk and high resource intensive interventions (in vitro fertilization [IVF], laparoscopy)  (<a class="graphic graphic_table graphicRef61307" href="/d/graphic/61307.html" rel="external">table 1</a>). (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lifestyle interventions</strong> – Lifestyle changes, such as discontinuing cigarette smoking and achieving a normal weight may increase fertility in women with unexplained infertility. (See <a class="local">'Lifestyle changes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Expectant management</strong> – Approximately 1 percent of couples with unexplained infertility will become pregnant per cycle with no intervention. Expectant management is a more appropriate option for couples in which the female partner is young (&lt;32 years of age) than for couples with older female partners. For women &gt;37 years of age, the ovarian follicular pool can become depleted during expectant management, resulting in untreatable infertility. (See <a class="local">'Low-resource interventions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment options</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ovulation induction</strong> – For treatment of women with unexplained infertility, we suggest three to four cycles of <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate (CC) or <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a> plus IUI for initial therapy rather than gonadotropin injections with IUI or IVF (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). CC/IUI is generally the first-line treatment for unexplained infertility because of its good clinical pregnancy rate, relatively low rate of multiple gestations, oral route of intake, lack of need for monitoring, and low cost. (See <a class="local">'Clomiphene plus IUI'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>In vitro fertilization (IVF)</strong> – For women who do not conceive with CC, AI, and IUI, we suggest IVF as the next step rather than gonadotropin therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_4" rel="external">Grade 2A</a>). IVF results in the highest per-cycle pregnancy rate in the shortest time interval. Limitations of IVF include high cost and high rates of multiple gestations, unless single embryo transfer is used. (See <a class="local">'In vitro fertilization'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>IVF is the intervention that will result in the highest per-cycle pregnancy rate in the shortest time interval. It is also the most costly intervention and has a high rate of high-order multiple pregnancy unless single embryo transfer is performed. (See <a class="local">'In vitro fertilization'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>If IVF is not an option </strong>– For women who do not conceive with CC or AI/IUI and for whom IVF is <strong>not</strong> an option, the choice and order of treatment steps vary by author. (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The section editor and one author (MH) offer laparoscopy for women with pelvic symptoms or ovulation induction with a second oral agent or gonadotropins for asymptomatic women. For symptomatic women, treatment following laparoscopy is determined by the intraoperative findings. Gonadotropin ovulation induction and IUI are used for asymptomatic women because they are established in the treatment of unexplained infertility and have higher rates of conception compared with CC/IUI or aromatase inhibitors, although they also result in greater rates of multiple gestations, including triplet pregnancies and higher. (See <a class="local">'Our approach'</a> above and <a class="local">'Gonadotropin injections with or without IUI'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>One author (WG) performs laparoscopy, rather than gonadotropin/IUI, as the next treatment step because a number of these women will have findings of endometriosis and/or adhesive disease, regardless of symptoms, and surgical treatment of endometriosis is associated with improved fertility rates but does not increase the risk of multiple gestation. After laparoscopy another course of CC/IUI is initiated. (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional options</strong> – For women with unexplained infertility who do not conceive with CC or AI/IUI, IVF, gonadotropin/IUI, or laparoscopy, alternate treatment options include ovulation induction with the aromatase inhibitor <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a>, donor-egg pregnancy, gestational surrogacy, adoption, and cessation of treatment. Letrozole treatment for ovulation induction is an off-label use of this medication. At this point in treatment, the next step is determined by the patient after extensive counseling with her fertility team. (See <a class="local">'Our approach'</a> above.) </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Carson SA, Kallen AN. Diagnosis and Management of Infertility: A Review. JAMA 2021; 326:65.</a></li><li><a class="nounderline abstract_t">Collins JA, Crosignani PG. Unexplained infertility: a review of diagnosis, prognosis, treatment efficacy and management. Int J Gynaecol Obstet 1992; 39:267.</a></li><li><a class="nounderline abstract_t">Templeton AA, Penney GC. The incidence, characteristics, and prognosis of patients whose infertility is unexplained. Fertil Steril 1982; 37:175.</a></li><li><a class="nounderline abstract_t">Guzick DS, Grefenstette I, Baffone K, et al. Infertility evaluation in fertile women: a model for assessing the efficacy of infertility testing. Hum Reprod 1994; 9:2306.</a></li><li><a class="nounderline abstract_t">Moghissi KS, Wallach EE. Unexplained infertility. Fertil Steril 1983; 39:5.</a></li><li><a class="nounderline abstract_t">Practice Committee of tAmerican Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss. Fertil Steril 2008; 90:S60.</a></li><li><a class="nounderline abstract_t">Blacker CM, Ginsburg KA, Leach RE, et al. Unexplained infertility: evaluation of the luteal phase; results of the National Center for Infertility Research at Michigan. Fertil Steril 1997; 67:437.</a></li><li><a class="nounderline abstract_t">Leach RE, Moghissi KS, Randolph JF, et al. Intensive hormone monitoring in women with unexplained infertility: evidence for subtle abnormalities suggestive of diminished ovarian reserve. Fertil Steril 1997; 68:413.</a></li><li><a class="nounderline abstract_t">Guzick DS, Carson SA, Coutifaris C, et al. Efficacy of superovulation and intrauterine insemination in the treatment of infertility. National Cooperative Reproductive Medicine Network. N Engl J Med 1999; 340:177.</a></li><li><a class="nounderline abstract_t">Pandian Z, Bhattacharya S, Vale L, Templeton A. In vitro fertilisation for unexplained subfertility. Cochrane Database Syst Rev 2005; :CD003357.</a></li><li><a class="nounderline abstract_t">Hull MG. Effectiveness of infertility treatments: choice and comparative analysis. Int J Gynaecol Obstet 1994; 47:99.</a></li><li><a class="nounderline abstract_t">Lessey BA. Assessment of endometrial receptivity. Fertil Steril 2011; 96:522.</a></li><li class="breakAll">All of Us Research Program. https://allofus.nih.gov/.</li><li><a class="nounderline abstract_t">Smith JF, Eisenberg ML, Millstein SG, et al. Fertility treatments and outcomes among couples seeking fertility care: data from a prospective fertility cohort in the United States. Fertil Steril 2011; 95:79.</a></li><li><a class="nounderline abstract_t">Farquhar CM, Liu E, Armstrong S, et al. Intrauterine insemination with ovarian stimulation versus expectant management for unexplained infertility (TUI): a pragmatic, open-label, randomised, controlled, two-centre trial. Lancet 2018; 391:441.</a></li><li><a class="nounderline abstract_t">Diamond MP, Legro RS, Coutifaris C, et al. Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility. N Engl J Med 2015; 373:1230.</a></li><li><a class="nounderline abstract_t">Practice Committee of the American Society for Reproductive Medicine. Electronic address: <span class="__cf_email__" data-cfemail="81e0f2f3ecc1e0f2f3ecafeef3e6">[email protected]</span>, Practice Committee of the American Society for Reproductive Medicine. Evidence-based treatments for couples with unexplained infertility: a guideline. Fertil Steril 2020; 113:305.</a></li><li class="breakAll">SART clinic summary report 2013 https://www.sartcorsonline.com/rptCSR_PublicMultYear.aspx?ClinicPKID=0.</li><li><a class="nounderline abstract_t">Marcoux S, Maheux R, Bérubé S. Laparoscopic surgery in infertile women with minimal or mild endometriosis. Canadian Collaborative Group on Endometriosis. N Engl J Med 1997; 337:217.</a></li><li class="breakAll">Letrozole prescribing information https://www.nlm.nih.gov/medlineplus/druginfo/meds/a698004.html (Accessed on December 17, 2015).</li><li><a class="nounderline abstract_t">Evers JL. Female subfertility. Lancet 2002; 360:151.</a></li><li><a class="nounderline abstract_t">van Eekelen R, Tjon-Kon-Fat RI, Bossuyt PMM, et al. Natural conception rates in couples with unexplained or mild male subfertility scheduled for fertility treatment: a secondary analysis of a randomized controlled trial. Hum Reprod 2018; 33:919.</a></li><li><a class="nounderline abstract_t">Hull MG, Glazener CM, Kelly NJ, et al. Population study of causes, treatment, and outcome of infertility. Br Med J (Clin Res Ed) 1985; 291:1693.</a></li><li><a class="nounderline abstract_t">Steures P, van der Steeg JW, Hompes PG, et al. Intrauterine insemination with controlled ovarian hyperstimulation versus expectant management for couples with unexplained subfertility and an intermediate prognosis: a randomised clinical trial. Lancet 2006; 368:216.</a></li><li><a class="nounderline abstract_t">Custers IM, van Rumste MM, van der Steeg JW, et al. Long-term outcome in couples with unexplained subfertility and an intermediate prognosis initially randomized between expectant management and immediate treatment. Hum Reprod 2012; 27:444.</a></li><li><a class="nounderline abstract_t">Barbieri RL. The initial fertility consultation: recommendations concerning cigarette smoking, body mass index, and alcohol and caffeine consumption. Am J Obstet Gynecol 2001; 185:1168.</a></li><li><a class="nounderline abstract_t">Wittemer C, Ohl J, Bailly M, et al. Does body mass index of infertile women have an impact on IVF procedure and outcome? J Assist Reprod Genet 2000; 17:547.</a></li><li><a class="nounderline abstract_t">Fedorcsák P, Dale PO, Storeng R, et al. Impact of overweight and underweight on assisted reproduction treatment. Hum Reprod 2004; 19:2523.</a></li><li><a class="nounderline abstract_t">Hughes E, Brown J, Collins JJ, Vanderkerchove P. Clomiphene citrate for unexplained subfertility in women. Cochrane Database Syst Rev 2010; :CD000057.</a></li><li><a class="nounderline abstract_t">Fisch P, Casper RF, Brown SE, et al. Unexplained infertility: evaluation of treatment with clomiphene citrate and human chorionic gonadotropin. Fertil Steril 1989; 51:828.</a></li><li><a class="nounderline abstract_t">Guzick DS, Sullivan MW, Adamson GD, et al. Efficacy of treatment for unexplained infertility. Fertil Steril 1998; 70:207.</a></li><li><a class="nounderline abstract_t">Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in infertile women: a committee opinion. Fertil Steril 2013; 100:341.</a></li><li><a class="nounderline abstract_t">Bhattacharya S, Harrild K, Mollison J, et al. Clomifene citrate or unstimulated intrauterine insemination compared with expectant management for unexplained infertility: pragmatic randomised controlled trial. BMJ 2008; 337:a716.</a></li><li class="breakAll">Merrill Dow Pharmaceuticals. Product information bulletin. Cincinnati Ohio 1972.</li><li><a class="nounderline abstract_t">Collins J. Global epidemiology of multiple birth. Reprod Biomed Online 2007; 15 Suppl 3:45.</a></li><li><a class="nounderline abstract_t">Cantineau AE, Cohlen BJ, Heineman MJ. Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with subfertility. Cochrane Database Syst Rev 2007; :CD005356.</a></li><li><a class="nounderline abstract_t">van Eekelen R, van Geloven N, van Wely M, et al. Is IUI with ovarian stimulation effective in couples with unexplained subfertility? Hum Reprod 2019; 34:84.</a></li><li><a class="nounderline abstract_t">Kosmas IP, Tatsioni A, Fatemi HM, et al. Human chorionic gonadotropin administration vs. luteinizing monitoring for intrauterine insemination timing, after administration of clomiphene citrate: a meta-analysis. Fertil Steril 2007; 87:607.</a></li><li><a class="nounderline abstract_t">Osuna C, Matorras R, Pijoan JI, Rodríguez-Escudero FJ. One versus two inseminations per cycle in intrauterine insemination with sperm from patients' husbands: a systematic review of the literature. Fertil Steril 2004; 82:17.</a></li><li><a class="nounderline abstract_t">Polyzos NP, Tzioras S, Mauri D, Tatsioni A. Double versus single intrauterine insemination for unexplained infertility: A meta-analysis of randomized trials. Fertil Steril 2010; 94:1261.</a></li><li><a class="nounderline abstract_t">Ragni G, Maggioni P, Guermandi E, et al. Efficacy of double intrauterine insemination in controlled ovarian hyperstimulation cycles. Fertil Steril 1999; 72:619.</a></li><li><a class="nounderline abstract_t">Randall GW, Gantt PA. Double vs. single intrauterine insemination per cycle: use in gonadotropin cycles and in diagnostic categories of ovulatory dysfunction and male factor infertility. J Reprod Med 2008; 53:196.</a></li><li><a class="nounderline abstract_t">Arab-Zozani M, Nastri CO. Single versus double intrauterine insemination (IUI) for pregnancy: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2017; 215:75.</a></li><li><a class="nounderline abstract_t">Custers IM, Steures P, Hompes P, et al. Intrauterine insemination: how many cycles should we perform? Hum Reprod 2008; 23:885.</a></li><li><a class="nounderline abstract_t">Dovey S, Sneeringer RM, Penzias AS. Clomiphene citrate and intrauterine insemination: analysis of more than 4100 cycles. Fertil Steril 2008; 90:2281.</a></li><li><a class="nounderline abstract_t">Liu A, Zheng C, Lang J, Chen W. Letrozole versus clomiphene citrate for unexplained infertility: a systematic review and meta-analysis. J Obstet Gynaecol Res 2014; 40:1205.</a></li><li><a class="nounderline abstract_t">ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice. Obstet Gynecol 2018; 131:1.</a></li><li><a class="nounderline abstract_t">Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 2014; 371:119.</a></li><li><a class="nounderline abstract_t">Tulandi T, Martin J, Al-Fadhli R, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 2006; 85:1761.</a></li><li><a class="nounderline abstract_t">Practice Committee of American Society for Reproductive Medicine. Multiple gestation associated with infertility therapy: an American Society for Reproductive Medicine Practice Committee opinion. Fertil Steril 2012; 97:825.</a></li><li><a class="nounderline abstract_t">Reindollar RH, Regan MM, Neumann PJ, et al. A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial. Fertil Steril 2010; 94:888.</a></li><li><a class="nounderline abstract_t">Zolton JR, Lindner PG, Terry N, et al. Gonadotropins versus oral ovarian stimulation agents for unexplained infertility: a systematic review and meta-analysis. Fertil Steril 2020; 113:417.</a></li><li><a class="nounderline abstract_t">Kansal-Kalra S, Milad MP, Grobman WA. In vitro fertilization (IVF) versus gonadotropins followed by IVF as treatment for primary infertility: a cost-based decision analysis. Fertil Steril 2005; 84:600.</a></li><li><a class="nounderline abstract_t">Pandian Z, Gibreel A, Bhattacharya S. In vitro fertilisation for unexplained subfertility. Cochrane Database Syst Rev 2012; :CD003357.</a></li><li><a class="nounderline abstract_t">Goldman MB, Thornton KL, Ryley D, et al. A randomized clinical trial to determine optimal infertility treatment in older couples: the Forty and Over Treatment Trial (FORT-T). Fertil Steril 2014; 101:1574.</a></li><li><a class="nounderline abstract_t">Aboulghar MA, Mansour RT, Serour GI, et al. Management of long-standing unexplained infertility: A prospective study. Am J Obstet Gynecol 1999; 181:371.</a></li><li><a class="nounderline abstract_t">Hughes E, Collins J, Vandekerckhove P. Bromocriptine for unexplained subfertility in women. Cochrane Database Syst Rev 2000; :CD000044.</a></li><li><a class="nounderline abstract_t">Hughes E, Tiffin G, Vandekerckhove P. Danazol for unexplained infertilty. Cochrane Database Syst Rev 2000; :CD000069.</a></li></ol></div><div id="topicVersionRevision">Topic 7410 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34228062" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis and Management of Infertility: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1361459" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Unexplained infertility: a review of diagnosis, prognosis, treatment efficacy and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7060767" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The incidence, characteristics, and prognosis of patients whose infertility is unexplained.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7714149" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Infertility evaluation in fertile women: a model for assessing the efficacy of infertility testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6336697" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Unexplained infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19007647" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Definitions of infertility and recurrent pregnancy loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9091327" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Unexplained infertility: evaluation of the luteal phase; results of the National Center for Infertility Research at Michigan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9314906" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Intensive hormone monitoring in women with unexplained infertility: evidence for subtle abnormalities suggestive of diminished ovarian reserve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9895397" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Efficacy of superovulation and intrauterine insemination in the treatment of infertility. National Cooperative Reproductive Medicine Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846658" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : In vitro fertilisation for unexplained subfertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7843496" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effectiveness of infertility treatments: choice and comparative analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880273" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Assessment of endometrial receptivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880273" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Assessment of endometrial receptivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20659733" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Fertility treatments and outcomes among couples seeking fertility care: data from a prospective fertility cohort in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29174128" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Intrauterine insemination with ovarian stimulation versus expectant management for unexplained infertility (TUI): a pragmatic, open-label, randomised, controlled, two-centre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26398071" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32106976" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Evidence-based treatments for couples with unexplained infertility: a guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32106976" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Evidence-based treatments for couples with unexplained infertility: a guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9227926" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Laparoscopic surgery in infertile women with minimal or mild endometriosis. Canadian Collaborative Group on Endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9227926" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Laparoscopic surgery in infertile women with minimal or mild endometriosis. Canadian Collaborative Group on Endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12126838" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Female subfertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29538638" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Natural conception rates in couples with unexplained or mild male subfertility scheduled for fertility treatment: a secondary analysis of a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3935248" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Population study of causes, treatment, and outcome of infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16844491" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Intrauterine insemination with controlled ovarian hyperstimulation versus expectant management for couples with unexplained subfertility and an intermediate prognosis: a randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22114108" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Long-term outcome in couples with unexplained subfertility and an intermediate prognosis initially randomized between expectant management and immediate treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11717652" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The initial fertility consultation: recommendations concerning cigarette smoking, body mass index, and alcohol and caffeine consumption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11209534" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Does body mass index of infertile women have an impact on IVF procedure and outcome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15319380" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Impact of overweight and underweight on assisted reproduction treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20091498" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clomiphene citrate for unexplained subfertility in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2707458" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Unexplained infertility: evaluation of treatment with clomiphene citrate and human chorionic gonadotropin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9696208" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Efficacy of treatment for unexplained infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23809505" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Use of clomiphene citrate in infertile women: a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18687718" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clomifene citrate or unstimulated intrauterine insemination compared with expectant management for unexplained infertility: pragmatic randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18687718" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clomifene citrate or unstimulated intrauterine insemination compared with expectant management for unexplained infertility: pragmatic randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18598609" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Global epidemiology of multiple birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17443584" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with subfertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30395266" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Is IUI with ovarian stimulation effective in couples with unexplained subfertility?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17173907" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Human chorionic gonadotropin administration vs. luteinizing monitoring for intrauterine insemination timing, after administration of clomiphene citrate: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15236980" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : One versus two inseminations per cycle in intrauterine insemination with sperm from patients' husbands: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19665705" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Double versus single intrauterine insemination for unexplained infertility: A meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10521098" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy of double intrauterine insemination in controlled ovarian hyperstimulation cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18441725" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Double vs. single intrauterine insemination per cycle: use in gonadotropin cycles and in diagnostic categories of ovulatory dysfunction and male factor infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28605667" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Single versus double intrauterine insemination (IUI) for pregnancy: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18263638" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Intrauterine insemination: how many cycles should we perform?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18191842" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clomiphene citrate and intrauterine insemination: analysis of more than 4100 cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24754848" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Letrozole versus clomiphene citrate for unexplained infertility: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29794680" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25006718" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16650422" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22192352" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Multiple gestation associated with infertility therapy: an American Society for Reproductive Medicine Practice Committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19531445" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31973903" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Gonadotropins versus oral ovarian stimulation agents for unexplained infertility: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16169391" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : In vitro fertilization (IVF) versus gonadotropins followed by IVF as treatment for primary infertility: a cost-based decision analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22513911" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : In vitro fertilisation for unexplained subfertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24796764" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A randomized clinical trial to determine optimal infertility treatment in older couples: the Forty and Over Treatment Trial (FORT-T).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10454685" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Management of long-standing unexplained infertility: A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10796473" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Bromocriptine for unexplained subfertility in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10796484" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Danazol for unexplained infertilty.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
